Japonicone A reversed the expression of 87 overlapping DEGs, including six hub genes, and its potential therapeutic effects on breast cancer were related to Cell cycle, Oocyte meiosis, p53 signaling pathway, Progesterone-mediated oocyte maturation, Viral carcinogenesis, HTLV-I infection, Pathways in cancer and TGF-beta signaling pathway (Fig. 7A). Here, TP53 is linked to breast carcinoma.